Trials / Completed
CompletedNCT00105508
Sarizotan HC1 in Patients With Parkinson's Disease Suffering From Treatment-associated Dyskinesia
A Double-blind, Placebo-controlled, Multicenter, Multinational Phase III Study to Evaluate the Safety and Efficacy of Sarizotan HCl 1 mg b.i.d. in Patients With Parkinson's Disease Suffering From Treatment-associated Dyskinesia
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 506 (actual)
- Sponsor
- EMD Serono · Industry
- Sex
- All
- Age
- 30 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to determine if Sarizotan HC1 1 mg b.i.d. (taken twice a day) is effective in the treatment of dyskinesia associated with dopaminergic treatment of Parkinson's disease (PD).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Sarizotan | Subjects will receive sarizotan 1 milligram orally twice daily for 24 weeks. |
| DRUG | Placebo | Subjects will receive placebo matched to sarizotan orally twice daily for 24 weeks. |
Timeline
- Start date
- 2004-09-30
- Primary completion
- 2006-02-28
- Completion
- 2006-02-28
- First posted
- 2005-03-16
- Last updated
- 2018-07-26
- Results posted
- 2018-07-26
Locations
31 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT00105508. Inclusion in this directory is not an endorsement.